Physician profile
John W Chatas
NPI 1083710107
$28,775.50
in general payments reported to CMS, 2019-2025
29 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,418 · 2020: $8,738 · 2021: $11K · 2022: $722 · 2023: $2,974 · 2024: $1,038 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,963 · Travel and Lodging: $2,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,962.57 |
| Travel and Lodging | $2,152.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $13,595.37 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Spectra Wavewriter |
| Painteq LLC | $6,519.49 | 2021 | |
| Saluda Medical Americas, INC. | $2,681.53 | 2023-2025 | Evoke Scs, Evoke |
| Vertiflex, INC. | $1,267.83 | 2019 | |
| Abbott Laboratories | $1,055.67 | 2019-2025 | Proclaim |
| Nevro Corp. | $708.42 | 2019-2024 | Senza |
| Vertos Medical, INC. | $670.06 | 2019-2024 | Mild Device Kit |
| Relievant Medsystems, INC. | $642.07 | 2020-2022 | |
| Abbvie INC. | $252.30 | 2022-2025 | Botox |
| Medtronic, INC. | $199.52 | 2021-2025 | Intellis Adaptivestim, Vanta Adaptivestim, Synchromedii |
| Globus Medical, INC. | $182.32 | 2025 | Senza |
| Spr Therapeutics, INC | $181.81 | 2021-2025 | Sprint Pns System |
| Bioventus LLC | $165.71 | 2019-2025 | Xcell |
| Spinal Simplicity, LLC | $86.61 | 2022-2025 | Ha Minuteman G3-R |
| Medtronic USA, INC. | $85.34 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $80.37 | 2019-2022 | |
| Intrinsic Therapeutics | $56.21 | 2022 | |
| Amgen INC. | $54.33 | 2019-2022 | |
| Si-Bone, INC. | $54.09 | 2023-2024 | |
| Stryker Corporation | $40.19 | 2019-2021 | |
| Biotronik Nro, INC. | $37.03 | 2025 | Prospera |
| Tersera Therapeutics LLC | $35.82 | 2019 | |
| Lilly USA, LLC | $28.95 | 2019 | |
| Scilex Pharmaceuticals INC. | $24.21 | 2019 | |
| Curonix LLC | $20.14 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nalu Medical, INC. | $16.02 | 2024 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.09 | 2019 | |
| Merit Medical Systems INC | $6.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chatas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.